www.finanznachrichten.de ·
68419422 pharming group n v pharming group reports first quarter 2026 financial results on track for joenja u s pediatric label expansion and launches in j 399
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedPharming Group's Q1 2026 results show mixed performance: RUCONEST decline but Joenja growth. Regulatory progress for Joenja in Japan and Europe supports future revenue expansion. No direct commodity or supply chain impact; commercial mechanism is company-specific product revenue and regulatory approval.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Pharming Group Q1 2026 total revenues US$72.4M, down 8% YoY
- RUCONEST revenue US$58.4M, down 15% YoY
- Joenja revenue US$14.1M, up 34% YoY
- Joenja approved in Japan for patients aged 4+
- CHMP positive opinion for Joenja in Europe, final decision Q2 2026
RUCONEST and Joenja revenues are expected to remain flat in the short term, with no immediate price/margin shock within 48 hours.
Sign in to see all sector verdicts, full thesis and counter-argument debate.